Similarly, the enrichment of JAK–STAT signaling supports the therapeutic use of JAK inhibitors, such as tofacitinib and upadacitinib, approved in ulcerative colitis [34,60,61]. The gene discussed is SOAT1; the disease is ulcerative colitis.